VivoSeq
Oncology

Blood Cancer

0

Pipeline Programs↗

9

Active Trials↗

8

Companies Involved↗

Blood Cancer is an early-stage landscape with 0 programs across 8 companies. The most active players are AstraZeneca, Eli Lilly, Sumitomo Pharma America, Inc..

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

40/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

PreclinicalSumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.

0 programs

PreclinicalA

AVM Biotechnology Inc

0 programs

PreclinicalBayer logo

Bayer

0 programs

PreclinicalS

Senti Biosciences

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Recruiting4 · 27%
Active, not recruiting4 · 27%
Completed2 · 13%
Terminated2 · 13%
Not yet recruiting1 · 7%
Available1 · 7%
Other1 · 7%

Clinical Trials

Trial Activity

15 trials

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
Recruiting·AstraZeneca logoAstraZeneca·Phase 1·NCT07064122·72 enrolled
Cord Blood Transplant in Adults With Blood Cancers
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT05884333·54 enrolled
Selumetinib and Azacitidine in High Risk Chronic Blood Cancers
Recruiting·UUniversity of Chicago·Phase 1·NCT03326310·18 enrolled
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
Recruiting·Eli Lilly logoEli Lilly·Phase 2·NCT07162181·13 enrolled
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
Active, not recruiting·GGeoVax, Inc.·Phase 2·NCT04977024·63 enrolled
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
Active, not recruiting·SSenti Biosciences·Phase 1·NCT06325748·21 enrolled
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
Active, not recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT05024045·316 enrolled
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Active, not recruiting·BeiGene logoBeiGene·Phase 1/2·NCT06697184·56 enrolled
How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers
Not yet recruiting·Sumitomo Pharma America, Inc. logoSumitomo Pharma America, Inc.·Phase 1·NCT07444268·8 enrolled
Phase I Trial of BAY1251152 for Advanced Blood Cancers
Completed·Bayer logoBayer·Phase 1·NCT02745743·21 enrolled
AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer
Completed·AstraZeneca logoAstraZeneca·Phase 1/2·NCT04630756·40 enrolled
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers
Terminated·UUniversity Health Network, Toronto·Phase 1/2·NCT04092179·27 enrolled
Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers
Terminated·MMirror Biologics, Inc.·Phase 1/2·NCT00861965·2 enrolled
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
Withdrawn·EEpizyme, Inc.·Phase 1/2·NCT05205252
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
Available·AAVM Biotechnology Inc·N/A·NCT05974410

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)